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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on the relationship between alpha-lipoic acid
(ALA) and the risk of insulin autoimmune syndrome (IAS). The Panel was also asked to advise on the
dose below which ALA added to foods is not expected to cause IAS. A review of all possible adverse
effects associated with consumption of ALA was not requested. This mandate refers to the procedure
under Article 8(2) of Regulation (EC) No 1925/2006 on addition of vitamins, minerals and certain other
substances to foods. No pre-established rule exists for the evaluation of the safety of foods when
classical toxicity tests cannot be used, e.g. for autoimmune diseases. Published scientific evidence was
retrieved through comprehensive literature searches, particularly 49 case reports in which IAS
developed following ALA consumption. In all cases, IAS resolved after a few weeks to months when
ALA was discontinued. No publication linking the intake of ALA naturally occurring in foods to IAS was
identified. The Panel concludes that the consumption of ALA added to foods, including food
supplements, is likely to increase the risk of developing IAS in individuals with certain genetic
polymorphisms, who cannot be readily identified without genetic testing. The plausible mechanism of
such an effect has not yet been fully elucidated. The incidence of IAS in Europe is low and likely lower
than in Japan where it has been estimated to be 0.017 per 100,000 inhabitants in 2017–2018.
Considering the limited data available, the risk associated with the development of IAS following ALA
consumption cannot be quantified precisely. An ALA dose below which IAS is not expected to occur is
likely to vary between individuals and cannot be determined from the available data.
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1. Introduction
1.1. Background
The Danish authorities requested the Commission to initiate the procedure under Article 8 of
Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other
substances to foods1 for the intake of alpha-lipoic acid in food supplements because of the potential
risk to health associated with the intake of this substance. Safety concerns associated with the use of
alpha-lipoic acid in food supplements have been outlined in a scientific opinion by the Danish National
Food Institute (DTU) on the safety of alpha-lipoic acid use in food supplements,2 and in an expert
opinion on the safety of placing dietary supplements with alpha-lipoic acid on the market for the
general population3 by the Belgian Superior Health Council.
The above-mentioned scientific assessments lay out the possible harmful effects associated with
the use of alpha-lipoic acid in food supplements, in particular a potential risk for Insulin Autoimmune
Syndrome and reports in clinical studies of several adverse effects.
Consequently, the Commission has initiated the procedure under Article 8 (2) of Regulation (EC) No
1925/2006 on the addition of vitamins and minerals and of certain other substances to foods, for the
intake of alpha-lipoic acid in food supplements.
1.2. Terms of Reference as provided by the requestor
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20024, the European Commission
asks EFSA to:
– Review the existing scientific data on the possible link between the intake of alpha-lipoic acid
and Insulin Autoimmune Syndrome.
– Provide advice on a dietary intake of alpha-lipoic acid intentionally added to foods that does not
give rise to concerns about Insulin Autoimmune Syndrome for the general population, and as
appropriate, for vulnerable subgroups of the population.
1.3. Interpretation of the Terms of Reference
The Panel understands that it is expected to provide information on the relationship between oral
consumption of alpha-lipoic acid (ALA, or thioctic acid) that is added to food, including food
supplements, and insulin autoimmune syndrome (IAS, or Hirata’s disease).
The Panel is also expected to provide advice on the dose below which ALA added to foods is not
expected to cause IAS in the general population or in vulnerable subgroups thereof.
In line with the mandate, it is out of the scope to review possible adverse effects other than IAS
associated with the oral consumption of ALA.
Also out of scope of the mandate are the assessment of metabolic/beneficial effect(s) of oral
consumption of ALA, a risk–benefit analysis of ALA supplementation and an exposure assessment of
ALA in the European population.
1.4. Context of the assessment
Article 8 of Regulation (EC) No 1925/2006 provides for a procedure for the regulatory management
of substances other than vitamins or minerals added to foods that may present a potential risk to
consumers. Upon its own initiative or on the basis of information provided by Member States, the
European Commission may ask EFSA for a scientific assessment of the safety of such a substance.4 On
the basis of EFSA’s assessment, the European Commission together with the Member States may
1 OJ L 404, 30.12.2006, p. 26.
2 ‘Safety of alpha-lipoic acid use in food supplements’, Danish National Food Institute, DTU Doc nr. 17/14450, 10.10.2017.
3 Avis du Conseil Superieur de la Sante N. 9274, ‘Innocuite de l’acide alpha-lipo€ıque dans les complements alimentaires’,
4.6.2015.
4 To date EFSA has delivered five scientific opinions in the context of Article 8(2) of Regulation (EU) No 1925/2006, i.e.
Scientific Opinions the safety of 1) Ephedra species, 2) Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille, 3)
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decide either to allow the use of the substance (with or without restrictions) in food, to prohibit the
use of the substance in food or to put the substance under scrutiny.
1.5. Previous assessments
ALA is used as an active ingredient in medicinal products mainly for the treatment of diabetic
neuropathy. It is also available as a food supplement.
Several scientific bodies in the area of food or medicinal products have published scientific
assessments on ALA within the European Union (EU), in particular in relation to the risk of IAS, that
are summarised in chronological order below.
In 2008, the French Food Safety Agency (AFSSA, 2008) (now called ANSES) published an opinion
on a draft regulatory text from the French risk management authorities, about the use of substances
with nutritional or physiological effect and plants or plant preparations in food supplements. Several
substances were considered, including ALA, for which no maximal dose was proposed in the draft
regulatory text. The French Food Safety Agency discussed amongst others a paper describing an acute
and a subacute toxicity study in rats (Cremer et al., 2006b). Regarding data in humans, the French
Food Safety Agency reviewed references on tolerance of ALA treatment for patients with diabetic
neuropathy and three published case reports of IAS (Furukawa et al., 2007; Ishida et al., 2007;
Takeuchi et al., 2007). Overall, it concluded that the risk of occurrence of this syndrome following
consumption of ALA cannot be excluded, but the risk is very low in the French population. Similar
considerations were repeated in another opinion of the French Food Safety Agency in 2011 on the
assessment of the risks associated with substances with nutritional or physiological effects with a view
to restricting or prohibiting their use in foodstuffs (ANSES, 2011).
The Superior Health Council of Belgium (2015) noted that ALA may be sold as a medicinal product
(e.g. in Germany) used for the treatment of diabetic neuropathy, and that adverse effects of treatment
with this substance have been observed without further details in the report. The Council
recommended that ALA should be used as a medicinal product instead of a food supplement and
consumed under medical supervision (as ALA was available as food supplement in Belgium at the time
when these conclusions were drawn).
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency
(EMA) published recommendations in 2015 for an update of the product information for medicinal
products containing thioctic acid (a synonym for ALA) and occurrence of IAS (EMA, 2015). It was
explained that the summary of product’s characteristics should be updated to indicate the following:
– Under ‘special warnings and precautions for use’
‘Cases of Insulin Autoimmune Syndrome (IAS) have been reported during treatment with
thioctic acid. Patients with human leukocyte antigen genotype such as HLA-DRB1*04:06 and
HLA-DRB1*04:03 alleles, are more susceptible to develop IAS when treated with thioctic acid.
HLA-DRB1*04:03 allele (susceptibility to IAS odds ratio: 1.6) is especially found in Caucasians,
with a higher prevalence in southern than in northern Europe and HLA-DRB1*04:06 allele
(susceptibility to IAS odds ratio: 56.6) is especially found in Japanese and Korean patients.
IAS should be considered in the differential diagnosis of spontaneous hypoglycaemia in
patients using thioctic acid [. . .].’
– Under ‘undesirable effects’
‘Immune system disorders
Frequency unknown: insulin autoimmune syndrome’’
Also, it was recommended that the package leaflet should indicate the following:
– ‘Patients with a certain human leukocyte antigen genotype (which is more frequent in
Japanese and Korean patients, but is also found in Caucasians) are more prone to
development of insulin autoimmune syndrome (disorder of the blood glucose regulating
hormones with pronounced lowering of blood sugar levels) when treated with thioctic acid.’
In 2017, the Danish National Food Institute (DTU) (DTU Food, 2017) described a number of
adverse effects other than IAS related to the consumption of ALA by humans, such as allergic skin
reactions, stomach ache, nausea, vomiting, diarrhoea and dizziness. DTU discussed a paper describing
an acute and a subacute toxicity study in rats (Cremer et al., 2006b) as well as another paper on a
chronic toxicity study also in rats (Cremer et al., 2006a). From these studies on endpoints unrelated to
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IAS, DTU concluded that ‘a dose of 60 mg alpha-lipoic acid per kg body weight per day is considered a
no observed adverse effect level (NOAEL)’. Using an uncertainty factor of 100 to take into account
inter and intra-species variability, DTU derived from the NOAEL ‘an upper limit of safe intake of alpha-
lipoic acid’ of ‘0.6 mg/kg body weight per day’, corresponding to ‘a maximum daily dose of 42 mg
alpha-lipoic acid for a person weighing 70 kg’. This NOAEL did not apply to the risk of developing IAS.
In this relation, DTU mentioned that ‘it is known that alpha-lipoic acid can cause insulin autoimmune
syndrome’, and that ‘since it is an immunological response (autoimmune response), it is assumed that
the dose consumed does not play a crucial role in the development of the disease’. DTU also discussed
data on the ‘strong genetic element in the development of IAS’. Finally, DTU stated the following:
‘Based on a calculated upper safe intake of 42 mg alpha-lipoic acid per person per day determined
from two rat studies and a general risk of increased incidence of IAS (irrespective of dosage level and
due to increased exposure of the population), DTU FOOD concludes that a supplement with a
recommended daily intake of 150–200 mg alpha-lipoic acid (as proposed by the applicants) gives rise
to safety concern’.
2. Data and methodologies
2.1. Data
For this scientific assessment, a protocol (Appendix B) has been developed in line with existing
methodology (EFSA, 2020).5
This Scientific Opinion is based on data that were retrieved through comprehensive literature
searches in Embase and PubMed on 4 September 2020 (and in March 2021, see further down) for
relevant publications in one of the EU languages. The Panel is aware that case reports published only
in non-European languages were not taken into account in the assessment. However, the
Panel considers, in view of the previous assessments conducted by other bodies, and the number of
published case reports identified in EU languages for this assessment, that such an exclusion did not
impact the overall assessment and conclusions.
The searches were conducted without applying limits to the date of publication. The database
searches were complemented by searches on websites of relevant institutions and authorities, such as
the US Food and Drug Administration (FDA), Health Canada or Food Standards Australia New Zealand
(FSANZ). The hits on these websites were added to the ones obtained from the databases and used in
particular for the general sections of this opinion.
Three searches were set up a priori. Only data in humans were considered for this assessment, as
no animal or in vitro model of IAS was identified.
1) Through search 1, EFSA retrieved case reports published in peer-reviewed journals of IAS
associated with ALA consumption. In some instances, these case reports were accompanied
by reviews of the evidence. The information provided in the review section of these papers
was also considered.
2) The purpose of search 2 was to retrieve literature reviews on IAS.
3) Search 3 was focussed on retrieving clinical trials in which ALA was administered either alone
or in combination. The original aim of search 3 was to identify clinical trials in humans in
which IAS or symptoms indicative of IAS have been reported as adverse effects. Following a
protocol amendment (No 1), search 3 was only used to retrieve pharmacokinetic studies in
humans as well as studies specifically designed to investigate safety of ALA in humans. While
relevant pharmacokinetic studies were identified, no relevant safety studies were found. The
list of references of the retrieved studies were screened for additional publications. Some
reviews that were found in search 3 were kept as background information and were also used
in the opinion.
Another protocol amendment (No 2) concerned signal data (published or unpublished) from
vigilance databases that were originally planned to be retrieved in the protocol but were not used (for
explanation, see Section 3.6).
The title and abstract screening was carried out in duplicate in Distiller SR®. Title and abstract
screening was done by EFSA staff members in parallel. Full-text screening was performed by a single
EFSA staff member (protocol amendment No 3). Any uncertainties were resolved by the Working
5 http://www.efsa.europa.eu/en/supporting/pub/en-1843
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Group. Data from case reports were extracted in tabular format in Microsoft Excel® by one EFSA staff
member and double-checked by another.
While all pertinent case reports have been included in the assessment, data coming from reviews
and pharmacokinetic studies were only described as appropriate. Previous assessments from other
scientific bodies were used for hand search in their lists of references, applying the inclusion criteria of
the present assessment.
No author was contacted to collect missing information.
An additional non-systematic search was conducted on 1 March 2021 after the public consultation
of the Opinion in Scopus and Embase, in order to retrieve evidence on the pharmacokinetics of
dihydrolipoic acid in humans, the reduced form of ALA. This was done following a comment received
during the public consultation to expand on the absorption, distribution, metabolism and excretion of
this form (in addition to the information already present in the opinion for ALA). The title, abstract and
full-text screening was carried out by a single reviewer in Distiller SR®. A hand search of the retrieved
publications was also performed.
The PRISMA flow charts of the four searches are included in Appendix A. A total of 3,094 titles and
abstracts were screened, of which 85 papers were identified as pertinent.
The eligibility criteria of the searches are reported in the protocol as Appendix B of this Scientific
Opinion. The search strings of the three initial searches are available in Appendix C. The search strings
for the additional search carried out after the public consultation are reported in Appendix D.
2.2. Methodologies
There is no pre-established rule for the evaluation of the safety of foods/substances in cases where
classical toxicity tests cannot be used as a basis of the assessment, such as for autoimmune diseases.
There is no guidance document available on how to perform such an assessment. In the present case,
the Panel relied on published case reports that linked the consumption of ALA to the development of
IAS.
In line with EFSA’s policy on openness and transparency, and in order for EFSA to receive
comments from the scientific community and stakeholders, the draft Scientific Opinion was released for
public consultation. The outcome of the public consultation is described in a technical report published
as Annex A to this Opinion.
2.3. Protocol amendments
1) Search 3 was only used to retrieve pharmacokinetic studies in humans as well as studies
specifically designed to investigate safety of ALA in humans instead of all clinical trials
conducted with ALA in humans.
2) Signal data from vigilance databases were not used in the assessment (for explanation, see
Section 3.6).
3) Full text screening was done by a single EFSA staff member instead of performing it in
duplicate. Any uncertainties were resolved by the Working Group.
4) Data on oral administration of ALA analogues, derivatives or metabolites were not included in
the assessment, as no case report was retrieved in which consumption of an ALA analogue,
derivative or metabolite was linked to the development of IAS.
5) An additional search was carried out on the pharmacokinetics of dihydrolipoic acid.
3. Assessment
3.1. Identity of alpha-lipoic acid
ALA (also called thioctic acid, C8H14O2S2, CAS Number: 1200-22-2 (racemic: 1077-28-7), IUPAC
name: 5-[(3R)-1,2-dithiolan-3-yl]pentanoic acid, molecular weight 206.3 g/mol) is an eight-carbon fatty
acid (Evans et al., 2002) that has a chiral centre in its 1,2-dithiolane ring (Ikuta et al., 2016).
Therefore, ALA exists in the form of two enantiomers: R-(+) and S-(–), for which formulas are
presented in Figure 1. The R-(+)-enantiomer is the naturally occurring form of ALA (Hermann et al.,
2014). It can be synthesised in the body from octanoic acid and cysteine (Bilska and Wlodek, 2005),
while the S-(–) form cannot (Ikuta et al., 2016). The S-(–) form is formed during the industrial
production of ALA by chemical synthesis (Yoon et al., 2016) (See Section 3.2.).
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3.2. Sources of alpha-lipoic acid, production process, stability and type
of formulations available
In its natural form, ALA occurs in foods of animal and plant origin as R-(+)-enantiomer, with the
highest content in tissues with a high metabolic activity such as the heart and lower contents in
muscle tissue. For example, pig hearts contain 1.1–1.6 mg/kg and calf muscles 0.07–0.15 mg/kg ALA
(Biewenga et al., 1997).
For the industrial production, several ways exist to produce ALA synthetically, as reviewed by the
US Food and Drug Administration (FDA) (Zhang et al., 2018). In particular, one high-yield synthetic
production process is cited in which dihydrolipoic acid, containing two sulfhydryl groups (see
Section 3.5.4) is produced from cyclohexanone, vinyl ethyl ether and thiourea and finally oxidised into
ALA. The Panel assumes that most industrially produced ALA is a racemic mixture rather than the pure
R-(+)-enantiomer.6
Dihydrolipoic acid can be a residue of the ALA synthesis or generated from the photolysis of ALA.
FDA states that impurities from the production process likely include, apart from dihydrolipoic acid,
oligomers resulting from its polymerisation and trace amounts of solvents and reagents. The European
Pharmacopoeia monograph for (RS)-ALA (Ph. Eur. 10.0, 4020-4021) identifies as specified impurities 5-
[(4RS)-1,2,3-trithian-4-yl]pentoic acid and a-hydro-x-hydroxypoly[sulfanediyl(3-sulfanyl-8-oxooctane-
1,8-diyl)], the latter being a mixture of ALA polymers. Limit for total impurities set in the European
Pharmacopoeia is 0.3% (HPLC-UV). No information was found in the retrieved literature on potential
contamination or adulteration of products containing ALA (see Appendix B, Section B.1.1).
ALA is light- and heat-sensitive. The FDA review indicates that it is likely to be stable in solid
formulations when protected from light and heat, but less stable in liquid formulations. The R-(+) form
is less stable than the racemic mixture (Zhang et al., 2018).
The Superior Health Council of Belgium (2015) reports that ALA as food supplement is mainly sold
in tablet or capsule form with recommended intakes usually between 300 and 600 mg/day.
The Panel notes that in the retrieved evidence there was no information on whether production
processes used to produce ALA for foods including food supplements substantially differ from those
used to produce ALA for use in medicinal products, or whether impurities or degradation products may
be different in nature or amount between food supplements and medicinal products. However,
considering that IAS has been observed to occur in conjunction with the intake of ALA as food
supplement as well as with its intake as medicinal product, the Panel considers that impurities or
degradation products were unlikely to play a role in the development of IAS (see Appendix B).
3.3. Biochemistry
ALA is present in all prokaryotic and eukaryotic cells. Together with its reduced form, dihydrolipoic
acid, it acts as a redox couple (Biewenga et al., 1997). ALA is covalently bound to a lysine of the E2
(dihydrolipoate acyltransferase) subunit of several 2-oxo acid dehydrogenase multienzyme complexes
(Teichert et al., 2003; Mignini et al., 2011) and acts as a cofactor that catalyses oxidative
decarboxylation of pyruvate, a-ketoglutarate and branched-chain a-ketoacids, formed during
transamination of leucine, isoleucine and valine. ALA is also an element of a mitochondrial complex
involved in glycine synthesis and degradation (Bilska and Wlodek, 2005). ALA is found both in
hydrophilic (cytoplasm, extracellular matrix) and hydrophobic (plasma membranes) environments
(Brufani and Figliola, 2014).
R-(+)-ALA  S-(–)-ALA 
Figure 1: Stereochemistry of alpha-lipoic acid
6 https://lpi.oregonstate.edu/mic/dietary-factors/lipoic-acid
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3.4. Absorption, distribution, metabolism and excretion of alpha-lipoic
acid
It has been suggested that R-(+)-ALA from natural sources is absorbed as lipoyllysine7 and is not
found unbound in humans. In contrast, supplemental ALA (racemic mixture or R-(+) form) is absorbed
as such and then found in its free form in the circulation (Biewenga et al., 1997). Free ALA in
circulation may also origin from the endogenous production of ALA. Apart from its free form and
lipoyllysine, ALA is also circulating as weakly bound to proteins via hydrogen bonds (Khan et al., 2015).
Supplemental ALA is readily absorbed. The Panel is not aware of any data on the potential
mechanisms of absorption (i.e. passive or active absorption) or on a potential interaction with other
substances. In the fasting state, several studies report mean time to maximum plasma concentrations
(Tmax) in adults mostly in the range of 0.5–1.0 h for both enantiomers (Gleiter et al., 1996; Hermann
et al., 1996, 2014; Teichert et al., 1998; Breithaupt-Gr€ogler et al., 1999; Evans et al., 2002; Zheng
et al., 2014; Rhee et al., 2018). Mignini et al. (2007) found a mean Tmax of up to 2 h, depending on
the formulation (i.e. solid or liquid). In the fed state, absorption is delayed. Gleiter et al. (1996)
observed mean Tmax of about 2.5 h and 1 h in the fed state and in the fasting state in the same
subjects, respectively. Liquid formulations seem to be absorbed more rapidly than solid formulations
(Hermann et al., 1996, 2014).
R-(+)-ALA is generally more bioavailable than the S-(-) form (Gleiter et al., 1996; Hermann et al.,
1996, 2014; Breithaupt-Gr€ogler et al., 1999). Breithaupt-Gr€ogler et al. (1999) reported the bioavailability
of R-(+)-ALA as being 40–50% higher than S-(-)-ALA, and Hermann et al. (2014) a bioavailability of R-
(+)-ALA being twice that of the S-(-) form (both based on maximum plasma concentrations (Cmax)). It
has been speculated that this difference might be attributed to different intestinal uptake mechanisms
between R-(+)-ALA and S-(-)-ALA (i.e. active, transporter-mediated absorption for the R-(+)-form vs.
passive or less effective active absorption for the S-(-) form) (Hermann et al., 2014).
Hermann et al. (2014) observed that, after body weight normalisation of data, ALA was consistently
more bioavailable in females than in males (n = 12 per sex) both for R-(+)-ALA and S-(-)-ALA. Areas
under the curve (AUCs) were on average 40% higher in females compared with males. Differences in
Tmax and Cmax, although higher in females, did not reach statistical significance. This sex-specific effect
was consistent for all formulations studied (i.e. liquid and various doses of solid formulations).
Pharmacokinetic parameters have been demonstrated to react in a linear and proportional dose-
dependent manner in the dose range of oral intakes of ALA of 50–600 mg (Breithaupt-Gr€ogler et al.,
1999).
ALA is rapidly removed from circulation. The mean half-life of ALA in plasma is generally described
to be about 30 min (Hermann et al., 1996; Biewenga et al., 1997; Teichert et al., 1998, 2003;
Breithaupt-Gr€ogler et al., 1999; Zheng et al., 2014; Rhee et al., 2018), though Mignini et al. (2007)
reported a mean half-life of around 6 h. Breithaupt-Gr€ogler et al. (1999) found that there was no
difference in half-life between R-(+)-ALA and S-(-)-ALA. A significant first pass effect (Teichert et al.,
2003; Zhang et al., 2018), in which total plasma clearance of ALA is in the same range as the plasma
flow in the liver, is responsible for the relatively low bioavailability of around 20–40%, depending on
the isomer and the formulation (i.e. liquid or solid) (Biewenga et al., 1997; Teichert et al., 2003).
Following absorption, ALA is taken up into cells (Bustamante et al., 1998) and reduced to
dihydrolipoic acid. Both are predominantly metabolised via b-oxidation. 4,6-Bis(methylthio)hexanoic
acid is the main metabolite in plasma (Teichert et al., 1998) and excreted in the urine (Teichert et al.,
2003; Zhang et al., 2018).
Only limited data are available on the concentrations of dihydrolipoic acid in human plasma and no
publication has been retrieved on its pharmacokinetics. Khan et al. (2011) reported mean (standard
deviation, SD) concentrations in plasma of 15 healthy volunteers (aged 22–25 years) of 173 (4.26) ng/mL
for dihydrolipoic acid and of 35 (5.64) ng/mL for ALA. Whether volunteers had received ALA supplements
or not, was not explicitly stated. Teichert and Preiss (1992) found dihydrolipoic acid concentrations in
plasma of six healthy non-supplemented volunteers of 33–145 ng/mL and ALA concentration of 1–25 ng/
mL after acid hydrolysis. In contrast, Haj-Yehia et al. (2000) showed in a chromatogram that
concentrations of dihydrolipoic acid in plasma of a volunteer who had received supplemental ALA were
lower than ALA concentrations (numeric values not reported). This is similar to what was shown by Khan
et al. (2015) for free endogenous ALA from plasma of a most likely non-supplemented individual. The
7 i.e. bound to the amino acid lysine.
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Panel notes that these data on the plasma ratio of dihydrolipoic acid/ALA are limited and insufficient to
conclude on which is the major circulating form.
3.5. Insulin autoimmune syndrome
3.5.1. Definition of insulin autoimmune syndrome
IAS is a an autoimmune disease characterised by spontaneous hypoglycaemic episodes due to high
titres of insulin autoantibodies (IAA), which determine a marked increase in total serum insulin, and
free insulin concentrations often within the normal range (Archambeaud-Mouveroux et al., 1989).
C-peptide and proinsulin concentrations are either elevated or within the normal range (depending
partly on whether IAA are also able to bind C-peptide and proinsulin and partly on the laboratory assay
used) (Censi et al., 2018b). IAS has been considered to occur in individuals that have not been
exposed to exogenous insulin, even though more recently, some cases of IAS in diabetic subjects who
received exogenous insulin have been reported (Cappellani et al., 2020).
Antibodies are mostly polyclonal IgG with kappa light chains (Cooper, 1999) and to a minor extent
with lambda light chains. However, the presence of IgA, IgM and monoclonal IgG has also been
described (Archambeaud-Mouveroux et al., 1989; Censi et al., 2018b).
3.5.2. Epidemiology of insulin autoimmune syndrome
IAS is rare: a survey conducted in the years 2017–2018, in Japanese hospitals with more than 300
beds (Yamada et al., 2020), identified 22 cases of IAS out of 785 patients with endogenous
hyperinsulinaemic hypoglycaemia who required treatment (i.e. 2.8%). Based on the assumption that
these 22 IAS cases were all the cases that had occurred in Japan in the years 2017–2018, the authors
calculated an incidence of IAS in the general population in Japan of 0.017 cases per 100.000
inhabitants in these years. In an older study (Takayama-Hasumi et al., 1990), conducted from 1979 to
1981 also in Japan, IAS was identified as the third cause (11.7% of cases) of severe spontaneous
hypoglycaemias treated in hospitals (after insulinoma and extrapancreatic neoplasms).
The incidence of IAS in Caucasians seems to be lower than in the Japanese population (Cappellani
et al., 2020). However, the number of case reports regarding Caucasians has been increasing in recent
years (Bresciani et al., 2011; Gullo et al., 2014; Michalopoulou Alevras et al., 2015; Lio et al., 2016;
Ferreira et al., 2017; Bolayir et al., 2018; Cappellani et al., 2018; Veltroni et al., 2018; Alag€uney et al.,
2019; Moffa et al., 2019; Cambria et al., 2020; Okuroglu et al., 2020; Yukina et al., 2020). It is,
however, difficult to estimate the actual incidence or conclude on a true increase in the disease
incidence among Caucasians, because of a possible underestimation of the occurrence of the
syndrome linked to a possible unawareness of the disease and its subsequent underdiagnosis and
underreporting (Cappellani et al., 2020).
3.5.3. Genetic determinants of insulin autoimmune syndrome
The presence of the Human Leukocyte Antigen HLA-DR4 (Uchigata et al., 2010), and in particular
the alleles DRB1*04:06 (most of the Asian cases), DRB1*04:03 (most of the Caucasian cases) and
DRB1*04:07 (Patel et al., 2020) and to a lesser extent DRB1*04:15 (Cappellani et al., 2018; Cambria
et al., 2020) are associated with an increased risk of developing the disease.
Glutamate at position 74 in all the alleles DRB1*04:03, DRB1*04:06 and DRB1*04:07 and serine at
position 37 (unique to DRB1*04:06) have been proposed to be responsible for this increased
predisposition for developing IAS (Yukina et al., 2020). DRB1*04:03 can be considered as the ancestral
allele from which DRB1*04:06 and DRB1*04:07 developed independently by nucleotide substitution or
by gene conversion (in case of DRB1*04:07) (Uchigata et al., 2000). The Panel was unable to retrieve
data on the amino acids that are present at position 74 and 37 in the allele DRB1*04:15.
As reported in the Allele Frequency Net Database (Gonzalez-Galarza Faviel et al., 2019),8
DRB1*04:03 was found to occur in various populations worldwide.9 In populations living in Europe, the
frequency is reported to range from 0.4% to 3.9% (data from Austria (1.5%), Germany (0.6–1.8%),
Greece (6%), Ireland (0.4%), Italy (1.0–2.1%), the Netherlands (2.2%), Poland (1.3%), Slovenia
(0.7–1%), Spain (3.1–4%), UK (0.7–3.9%), (Gonzalez-Galarza Faviel et al., 2019) and France (1.9%)
8 http://www.allelefrequencies.net/
9 As case reports on IAS associated with ALA are mainly available for Europe as well as Japan and South Korea, allele
frequencies are only reported for these two regions.
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(Uchigata et al., 2000)). In comparison, in Japan and South Korea, the prevalence is 1.6–12.3%
(Uchigata et al., 2000; Gonzalez-Galarza Faviel et al., 2019).
DRB1*04:06 is mostly present in East Asian populations (e.g. prevalence in Japan between 5.3%
and 13.2%), while, in Europe, it is between 0.1 and 1% (data from studies in Italy (1%), the
Netherlands (0.2%), Poland (0.1%) and Spain (0.5–0.6%)(Gonzalez-Galarza Faviel et al., 2019) and
France (0.3%) (Uchigata et al., 2000).
The prevalence of DRB1*04:07 in Europe has been observed to be in the range of 0.5–3.4%; in
Japan and South Korea, it is 0.3–2.8% (Uchigata et al., 2000; Gonzalez-Galarza Faviel et al., 2019).
The prevalence of DRB1*04:15 was investigated only in a limited number of studies and countries.
The only study which detected DRB1*04:15 was a study in Poland which found DRB1*04:15 in one
participant among 23,595 individuals. In none of the other studies, an individual carrying the
DRB1*04:15 was detected.
3.5.4. Pathophysiology of insulin autoimmune syndrome
IAS has been described as an autoimmune disease which may develop after the intake of
substances containing a sulfhydryl group (such as methimazole or dihydrolipoic acid; see Section 3.2).
However, IAS can also be triggered by viral infections and, in some cases, the trigger cannot be
identified. It may be sporadic, or may occur together with other autoimmune diseases (Archambeaud-
Mouveroux et al., 1989).
It has been proposed that substances containing sulfhydryl groups may cleave one disulfide bond
of insulin, resulting in structural modification and increased immunogenicity (Cappellani et al., 2020).
The resulting peptides have been shown to bind to gene products of DRB1*04:06. This leads to the
insulin-specific proliferation of T cells (Ito et al., 1993), and the subsequent production of IAA by B
cells.
Wasada et al. (1988) performed a study in which methimazole was incubated together with
biosynthetic recombinant human insulin. Authors concluded that insulin appeared not to be structurally
changed, although they did not directly investigate cleavage of disulfide bonds. Even if in vitro
antibody binding of insulin that had been incubated with methimazole was not observed, the
Panel notes that this does not allow to conclude on the inability of the incubated insulin to induce the
production of IAA.
Most authors hypothesise that IAA bind to endogenous insulin that is released from beta-cells in
response to a glucose stimulus. Insufficient free insulin is therefore available, causing a temporary
hyperglycaemia. This hyperglycaemia stimulates insulin secretion further. When the IAA-insulin
complexes dissociate post-prandially, biologically active insulin is released into circulation, resulting in
an excess of insulin and a subsequent hypoglycaemia (Ismail, 2016; Censi et al., 2018a; Cappellani
et al., 2020). Hypoglycaemia typically occurs within 2–6 h post-prandially with varying severity, as the
half-life of insulin in IAS is increased from minutes to hours. The severity of hypoglycaemia depends on
the antibody characteristics (i.e. binding capacity and affinity that determines the dissociation rate)
and their titres (Ismail, 2016). High capacity/low affinity antibodies are more likely to cause
hypoglycaemia (Redmon and Nuttall, 1999).
The hypothesis mentioned above was supported by Dozio et al. (1998) who administered 125I-
labelled insulin intravenously to a patient with IAS and a healthy volunteer. In the healthy subject,
radiolabelled insulin was quickly removed from plasma and taken up by the liver and the kidney. In the
IAS patient, radioactivity remained in the blood with hardly any uptake by the liver and kidney; 93.6%
of the 125I-labelled insulin was bound to antibodies.
In some parts of the population, IAA are present in serum and are not associated with adverse
effects. For example, Sodoyez et al. (1990) reported the presence (> mean + 3SD) of IAA in 1% of
2,200 healthy blood donors. Hattori et al. (2014) found IAA in 2.7% (of 263) of type 2 diabetics never
having received insulin. Cooper (1999) cited a study in which 6% (of 206) of patients treated with
methimazole (a substance associated with an increased risk of developing IAS) had IAA without
developing symptoms of IAS. In that study, IAA insulin-binding capacity was lower than usually
observed in IAS; the IAA concentrations peaked 2–3 months after methimazole administration and
declined thereafter to almost undetectable levels. In addition, Cooper (1999) mentioned another report
in which also 6% (of 95) patients treated with methimazole or carbimazole had IAA. The Panel notes
that this indicates that IAA with different affinities exist. Another possible explanation could be that
there is a threshold below which IAA do not cause adverse effects.
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The Panel notes that there is a plausible mechanism by which ALA may increase the risk of
developing IAS in individuals with certain genetic polymorphisms: cleavage of endogenous insulin,
insulin-specific proliferation of T cells, subsequent production of IAA by B cells, binding of IAA to
endogenous insulin, spontaneous dissociation of IAA-insulin complexes with an excess of insulin in
circulation. However, this mechanism has not yet been fully elucidated.
3.5.5. Symptoms of insulin autoimmune syndrome
IAS is most often associated with post-prandial hypoglycaemia (Okuroglu et al., 2020). The nature
of the symptoms is neuroglycopenic (e.g. behavioural changes, confusion, fatigue, seizures and loss of
consciousness), neurogenic (e.g. palpitations, tremor, anxiety) or cholinergic (e.g. sweating, hunger,
paresthesia) (Davi et al., 2017; Censi et al., 2018b). Symptoms typically resolve with food intake.
Fasting hypoglycaemia occurred in only a few cases (Cappellani et al., 2020).
IAS usually resolves within a few months once the trigger (see Section 3.5.4) is removed (hence
the symptoms disappear). However, some patients require pharmacological treatment (Cappellani
et al., 2020). When the trigger is re-introduced, the syndrome may reappear (Bae et al., 2013); see
Table 1.
3.6. Summary of case reports linking alpha-lipoic acid intake with
insulin autoimmune syndrome
From the comprehensive literature search, 49 cases of IAS linked to the consumption of ALA as
medicinal product or as food supplement were retrieved that were published as case reports or part of
reviews published in English (see Table 1). Case reports only published in non-European languages
were not considered as part of this Opinion (see Section 2.1). In all cases, authors confirmed that
circulating IAA were present. However, in the case report series described by Gullo et al. (2014) (n = 6),
the assay that was used to determine IAA was not specific for IAA.
Of the 49 cases identified in the literature, 20 occurred in Europe, out of which 19 were presumably
Caucasians (one was a woman of Sri Lankan origin). Most Caucasian cases were reported for Italy (n = 13).
One case was reported in Spain and one in Portugal, three in Turkey and one in Russia. Outside Europe, the
majority of cases were observed in Japan (n = 22), three were reported in South Korea and four in India
(supposedly all of South and East Asian origin, i.e. 30 cases in individuals with Asian ethnicity in total
(including the woman of Sri Lankan origin diagnosed in Italy)).
There was a predominance of female cases (41 out of 49) reported. Ages ranged from 28 to 82
years.
For 18 of the 49 cases in Table 1, the amount of ALA was reported and for 22 cases the duration of
intake was given. The intake varied between 200 and 800 mg/day. The time to onset in the
investigated case reports ranged from 1 week to 4 months (7–120 days). There was no obvious
association between dose and time to onset. However, for several cases, information on the dose or
duration of consumption or both was not available (e.g. 24 cases reporting neither the dose nor the
duration of consumption).
Among the cases, one South Korean 67-year-old woman underwent two accidental re-challenges
with ALA. In all three instances, in which she had consumed ALA in amounts of 600 mg/day, she
developed IAS, which completely resolved before each re-challenge. Also in other cases, IAS resolved
after a few weeks to months when ALA was discontinued (see Table 1).
Out of the 49 cases, data on health status, other possible concomitant medication and HLA class
DRB1* genotype were available for 26, 20 and 38 cases, respectively. The type of signs and symptoms
occurring were reported for 27 cases. In 12 of those cases, subjects lost consciousness or went into
hypoglycaemic coma. Other symptoms reported were mostly sweating, tremors, dizziness, fatigue,
weakness, confusion, hunger and palpitations.
Nineteen individuals were identified as carrying the DRB1*04:06 allele, 14 had DRB1*04:03, two
DRB1*04:15 and three individuals were identified as subtypes DRB1*04. No cases associated with
DRB1*04:07 were found. The predominant allele in the 19 cases of Caucasian origin diagnosed in
Europe was DRB1*04:03 (11 cases). The alleles DRB1*04:06 and DRB1*04:15 were found in two
cases and one case, respectively. One case was identified as DRB1*04 and in four cases no
information was available.
In 44 cases, no concomitant intake of other substances that are potential triggers of IAS, was
reported. In four cases, omeprazole was taken and in one case gliclazide. For both substances, only
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one case report each exists in which the development of IAS was associated with the use of the
substance (as reported in the review by Cappellani et al. (2020)). The woman who had consumed
gliclazide (Bae et al., 2013) had done this prior to the ingestion of ALA and symptoms of IAS started
only after the intake of ALA. In addition, she developed two additional episodes of IAS upon re-
exposure to ALA (see South Korean case described above). Given the wide-spread use of these
substances, the Panel considers it unlikely that gliclazide or omeprazole were involved in the
development of IAS in these cases.
The Panel notes that the one case (Bae et al., 2013) in which evidence of a double re-challenge
was available allows to attribute the development of IAS with a high probability to the consumption of
ALA. In addition, similar signs and symptoms occurred in the 27 cases for which this information was
available. The development of symptoms has always been preceded by the consumption of ALA either
as food supplement or medicinal product, in 44 cases without concomitant intake of other substances
that have been reported to be a potential trigger of IAS. The reported times to onset of IAS are
compatible with the emergence of an autoimmune disease. IAS resolved upon withdrawal of ALA after
several weeks to months. These observations are in line with the plausible mechanism that has been
put forward by which consumption of ALA could increase the risk of developing IAS (see
Section 3.5.4).
The Panel considers that there is an association between the consumption of ALA and an increased
risk of development of IAS in individuals with certain polymorphisms in the HLA region (see
Section 3.5.3 on genetic determinants).
As conclusions on an association between the consumption of ALA and an increased risk of
development of IAS could be drawn from published case reports, the data retrieval from vigilance
databases and adverse event reports from clinical trials was not further pursued as this would have
not changed the conclusions of the Panel derived from the case reports. The same applies to sales
data and data from food business operators’ post-marketing surveillance systems.
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Table 1: Summary of case reports reporting on insulin autoimmune syndrome (IAS) related to consumption of alpha-lipoic acid (ALA, or thioctic acid)
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AR: Argentina; d: day(s); ASA: acetylsalicylic acid; ES: Spain; F: female; hr: hour(s); HLA: human leukocyte antigen; IN: India; IT: Italy; JP: Japan; KR: Korea, Republic of; LK: Sri Lanka; M: male;
mo: month(s); NR: not reported; NSAIDs: non-steroidal anti-inflammatory drugs; PT: Portugal; RU: Russia Federation; T2DM: type 2 diabetes mellitus; TR: Turkey; wk: week(s); y: year(s).
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3.7. Dose below which insulin autoimmune syndrome is not expected to
occur
The lowest ALA intake that was associated with the development of IAS in the case reports
described in Section 3.6 was reported to be 200 mg/day. However, no data are available that would
allow a judgement to be made on whether IAS also occurs at lower doses. The Panel notes that
generally the susceptibility of individuals to triggers of autoimmune diseases varies. It is therefore likely
that this is also the case for IAS.
With respect to the NOAEL (0.6 mg/kg body weight per day) proposed by DTU, the Panel notes
that this was based on toxicological endpoints unrelated to IAS and therefore does not necessarily
protect from the development of IAS. In addition, the Panel notes that standard toxicity tests are not
suitable for determining a threshold below which an autoimmune disease is unlikely to occur (see
Section 2.2).
The Panel considers that, based on the data available, a dose below which IAS is not expected to
occur cannot be derived, neither for the general population nor for vulnerable sub-groups thereof.
4. Conclusions
The Panel concludes that the consumption of ALA added to foods, including food supplements, is
likely to lead to an increased risk of development of IAS in individuals with certain genetic
polymorphisms. The plausible mechanism by which ALA may increase this risk has not yet been fully
elucidated. These conclusions are based on the review of 49 case reports in which IAS developed
following ALA consumption. In the reviewed cases, IAS resolved a few weeks to months after ALA was
discontinued.
The Panel has not identified any publication linking the intake of ALA naturally occurring in foods to IAS.
The prevalence of the three main HLA alleles associated with an increased risk of development of
IAS has been reported to be around 0.1–3.9% in Europe, depending on the alleles and the country
(Uchigata et al., 2000; Gonzalez-Galarza Faviel et al., 2019). The Panel notes that the individuals
carrying the relevant polymorphisms cannot be readily identified without genetic testing.
The incidence of IAS (of all causes) for the years 2017–2018 in the general population in Japan has
been estimated to be 0.017 per 100,000 inhabitants (i.e. a total of 22 cases in these years) (Yamada
et al., 2020). The incidence in Europe is likely to be lower, considering that the prevalence of alleles
associated with an increased risk of development of IAS is less frequent in populations with Caucasian
than Asian ethnicity. However, based on the limited data available, the Panel concludes that the
incidence of IAS in Europe and the risk associated with the development of IAS following consumption
of ALA cannot be quantified either for the general population or for sub-groups or individuals with
genetic susceptibility.
The Panel also concludes that an ALA dose below which IAS is not expected to occur is likely to
vary between individuals and can therefore not be determined based on the data that are available.
5. Uncertainties
The following sources of uncertainties have been detected:
• There is a lack of information on whether the industrial production of ALA that is used in food
supplements differs from the one of ALA used in medicinal products, i.e. whether ALA for foods
and ALA for pharmaceutical production are interchangeable;
• Publications in non-EU languages have not been considered;
• It is likely that not all cases of IAS following ALA consumption in Europe have been published;
• There is likely a possible underestimation of the occurrence of IAS that is linked to a possible
unawareness of the disease and its subsequent underdiagnosis and underreporting.
• A plausible mechanism by which ALA may trigger IAS in individuals with certain genetic
polymorphisms has been suggested, but it still needs to be demonstrated.
• Even though data on allele frequency is available for a number of European countries, data
covering a sufficiently large representative sample of the whole EU population is missing.
The Panel acknowledges these uncertainties, but they do not diminish the scientific conclusions.
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6. Recommendations
In order to reduce the uncertainties, the Panel has identified the following recommendations for
research:
• Elucidation of the mechanism of action by which ALA increases the risk of developing IAS;
• Investigation of the incidence of IAS in the EU also in conjunction with the use of ALA;
• Investigation of the prevalence of HLA alleles associated with an increased risk of development
of IAS in a representative sample of the EU population.
7. Documentation as provided to EFSA
The following documentation was provided together with the mandate from the European
Commission:
• DTU Food, 2017. Safety of alpha-lipoic acid use in food supplements. DTU Doc nr. 17/14450, 5 pp.
• Superior Health Council of Belgium, 2015. Innocuite de l’acide alpha-lipo€ıque dans les
complements alimentaires. Avis du Conseil Superieur de la Sante No 9274, 10 pp.
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Abbreviations
AFSSA French Food Safety Agency
ALA alpha-lipoic acid
ANSES French Agency for Food, Environmental and Occupational Health and Safety
ASA acetyl salicylic acid
CAS Chemical Abstracts Service
Cmax maximum plasma concentrations
DTU Danish National Food Institute
EINECS European Inventory of Existing Chemical Substances
EKE expert knowledge elicitation
EMA European Medicines Agency
FDA US Food and Drug Administration
FSANZ Food Safety Australia New Zealand
HLA human leukocyte antigen
HPLC high-performance liquid chromatography
IAA insulin autoantibodies
IAS insulin autoimmune syndrome
IgA immunoglobulin A
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IgG immunoglobulin G
IgM immunoglobulin M
IUPAC International Union of Pure and Applied Chemistry
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
NOAEL no observed adverse effect level
Ph. Eur. European Pharmacopeia
PRAC Pharmacovigilance Risk Assessment Committee
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SD standard deviation
Tmax mean time to maximal plasma concentrations
UV ultraviolet
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Appendix A – PRISMA10 flow charts for the four literature searches
PRISMA flow chart search 1
Aimed at identifying case reports that link the development of IAS to the intake of ALA
PRISMA flow chart search 2
Aimed at identifying reviews on IAS
10 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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PRISMA flow chart search 3
Aimed at identifying pharmacokinetic studies and safety studies in humans
PRISMA flow chart search 4
Aimed at identifying studies on pharmacokinetics of dihydrolipoic acid in humans
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Appendix B – Protocol for the assessment of the relationship between
intake of alpha-lipoic acid (thioctic acid) and the risk of insulin
autoimmune syndrome
B.1. Problem formulation and planned approach towards the evidence
retrieval from the scientific literature
The following protocol has been developed in line with existing methodology (EFSA, 2020).
B.1.1. Assessment questions and sub-questions
In order to answer the Terms of Reference (ToR) as interpreted in Section 1.3, the Panel considers
that the following questions and subquestions need to be answered.
1) Identity of the ALA
o What are the chemical structure, the stereochemistry, the nomenclature (e.g. IUPAC
chemical name, CAS number, EINECS number)?
o What are the synonyms that are used to refer to the same substance?
o Analogues, derivatives, metabolites that are on the market?
o Is the substance occurring also naturally in food or is it only produced synthetically?
o How is ALA that is used in food supplements produced (e.g. source material, process)?
o Is there any difference between ALA used for food supplements and the one used for
medicines (structure, purity, production, source etc.)?
o How stable is ALA throughout shelf-life, are there any degradation products that are
produced that need to be considered?
o Are there impurities or contaminants in industrial ALA? If yes, are they related to the
mode of production? Is there data in the literature pertaining on contamination or
adulteration of ALA?
2) How is ALA absorbed, distributed, metabolised, excreted?
o Is ALA absorbed as such or are there any modifications in the gastro-intestinal tract
before absorption?
o What is its bioavailability? Are there bioavailability variations between individuals?
o What are the mechanisms regulating ALA absorption and distribution: transporters or
passive absorption, interaction with other substances/nutrients, circulating forms? What
are the metabolites of ALA?
o Which metabolic pathways are involved?
o Are there any interindividual differences in metabolism (that could lead to a higher
susceptibility of certain individuals than others)?
o How long is the half-life of ALA and its metabolites in blood circulation?
o Can ALA be accumulated in any form in the organism?
o How are ALA and its metabolites excreted?
3) What is IAS?
o What are the prevalence and incidence of the disease?
o Which is the aetiology of the disease (are there any other causes than ALA that would
need to be considered when evaluating the data on the link between ALA and the
disease)?
o Which polymorphisms have been associated with a higher risk of developing the disease
and what are the reasons?
o Are there any vulnerable sub-populations that can be readily defined? Are there
subpopulations with certain recognisable characteristics (with no need for genetic
testing) that have a higher susceptibility for the disease? Are children, elderly, lactating or
pregnant women at a higher/lower risk?
o What is the definition and pathophysiology of the disease?
o What are symptoms of the disease and its differential diagnosis?
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4) What is the association between ALA and IAS in humans?
o Which previous assessments from official scientific bodies are available and what are the
conclusions?
o Which are documented case reports in humans available in the literature?
o Are there any additional reports in European Nutravigilance databases of European
Member States or the EMA Eudravigilance database, not yet published in the literature?
o IAS reported in clinical trials.
o How strong is the association (how reliable was the ascertainment of the disease, how reliable was
the exposure assessment, are there data on challenge-re-challenge)?
o Has a causal relationship between ALA and IAS been established?
o What are the mechanisms of action involved in the detrimental effects of ALA?
5) What is the minimum eliciting dose?
o At which doses of ALA and exposure durations was IAS observed in well documented cases?
o Is there any health-based guidance value that could be set from the data?
B.1.2. Formulation of the sub-questions
For each of the questions above, the objectives of the sub-questions are as follows:
1) Identity of the ALA
o Objective 1: Map the main characteristics of ALA (chemical structure, enantiomer, natural
or synthetic occurrence)
o Objective 2: Identify synonyms for ALA
o Objective 3: Identify the production process of ALA for food supplements
o Objective 4: Compare the production/source of ALA for medical or food purpose
o Objective 5: Identify the shelf-life of ALA and whether degradation products could have
effects
2) How is ALA absorbed, distributed, metabolised, excreted?
o Objective 1: Identify the mechanisms of absorption, distribution, metabolisation, storage
and excretion of ALA
3) What is IAS?
o Objective 1: Map the main characteristics of IAS (symptoms, pathophysiology, causes of
the disease)
o Objective 2: Identify genetical predisposition to developing IAS
o Objective 3: Identify vulnerable sub-populations
o Objective 4: Prevalence and incidence of the disease
4) What is the association between ALA and IAS in humans?
o Objective 1: Identify the link between the intake of ALA and IAS.
5) What is the minimum eliciting dose?
o Objective 1: based on the literature mentioned before, identify, if possible, a no observed
adverse effect level (NOAEL) of ALA intentionally added to foods regarding IAS for the
general population and vulnerable sub-groups.
B.1.3. Definition of the search strategy and eligibility criteria for study
selection (i.e. evidence needs)
Questions 1 and 2 (Section B.1.1) will be answered following a narrative approach (i.e. no
comprehensive search, no data extraction forms), while questions 3, 4 and 5 will be answered based
on a comprehensive literature search, further described afterwards, and considering also other types
of data (e.g. reports from relevant scientific institutions and authorities, such as FDA, Health Canada,
Australia or New Zealand authorities). Information for questions 1 and 2 will be retrieved from relevant
websites, books and publications.
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For question 4 (What is the association between ALA and IAS in humans?), three types of data are
expected:
o Published trials that would report IAS as an adverse effect:
PICO framework11: (p) general population (i) consuming ALA or other drugs/substances
vs. (c) placebo or another comparator (o) developing IAS.
o Published case reports of IAS that would report the occurrence of IAS in a limited number of
individuals and the investigation to identify the cause (e.g. previous exposure to ALA or
another drug)
PO framework12: (p) the individual(s) that is/are described in the case reports, (o) that
developed IAS.
o Other types of data (e.g. relevant institutions and authorities, such as FDA, Health Canada,
Australia or New Zealand authorities)
In order to answer the questions 3, 4 and 5 identified above (section B.1.1 of the protocol), the
following dedicated comprehensive literature searches will be conducted by EFSA’s information
specialist, in Embase and PubMed, with no limitation on the date of publication and limiting the search
to EU languages. The search strings that will be used can be found in Appendix C.
The following inclusion and exclusion criteria will be applied:
– Search 1 related to Q4 (What is the association between ALA and IAS in humans?): Papers
(intervention or observational studies) on oral consumption of ALA in humans and IAS
• Inclusion:
▪ Trials (also single arm) on oral consumption of ALA as food, supplement or medicinal
product, also in combination with other substances, in humans that report on IAS
▪ Observational studies, in particular case reports, on the occurrence of IAS in a limited
number of individuals (that may report on the investigation to identify the cause,
possibly ALA, only in the full text)
▪ Abstracts of conferences on potential case reports
▪ Statements/opinions from competent authorities e.g. US FDA, Health Canada, etc.
▪ All population independently of age, healthy/disease status, ethnicity, etc.
▪ ALA in different forms i.e. tablets, capsules, etc. (even with the same dose)
• Exclusion:
▪ Protocols
▪ Studies on animals or cells as no animal or in vitro model of IAS was identified
▪ Reviews/meta-analyses
▪ Studies not on ALA and/or not on IAS
▪ Studies not on oral consumption (e.g. injection of ALA)
– Search 2 related to Q3 (What is IAS?): Reviews (systematic or narrative) on IAS
• Inclusion: review (narrative or systematic including also meta-analysis) on IAS (whatever
aspects of this disease) or autoimmune reaction related to insulin or hypoglycaemia or
autoimmune polyendocrine syndrome.
▪ NB: The purpose of this question is to identify plausible mechanisms (in humans, and
possibly also from data on animal or cell cultures), if reported in the reviews. This will be
discussed in a dedicated section of the opinion.
• Exclusion:
▪ All types of intervention or observational studies
▪ Protocols, abstracts of conference/congress/symposium
▪ Reviews not on IAS or autoimmune reaction related to insulin or hypoglycaemia or
autoimmune polyendocrine syndrome
11 Population (p), Intervention (i), Comparator (c) and Outcome (o) in a question about an intervention effect.
12 Population (p) and Outcome (o) in a descriptive question.
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– Search 3: Clinical trials on oral consumption of ALA
• Trials on oral consumption of ALA, alone or in combination, as food, supplement or
medicinal product that report on side effects.
• Exclusion:
▪ Protocols, abstracts of conference/congress/symposium
▪ Reviews/meta-analyses
▪ Studies not on ALA
▪ Studies not on oral consumption
Regarding the grey literature, additional searches will be performed on the websites of relevant
institutions and authorities, such as FDA, Health Canada, Australia or New Zealand authorities.
Websites will be browsed or searched to retrieve published reports on the relationship of ALA and IAS.
Methods to retrieve the information will be reported. Vigilance databases will also be searched to
retrieve case reports not published elsewhere.
B.1.4. Definition of the methods for selecting studies for inclusion/
exclusion
For questions 3, 4 and 5 of section B.1.1, the screening will be done in duplicate by EFSA staff
members using DistillerSR (Evidence Partners, Ottawa, Canada), at the level of the title and abstract
and then at the level of the full text. Conflicts that might arise will be discussed first amongst
the two reviewers of that study and if the conflict is not solved all reviewers will be involved. The
references will then be exported to EndNote®.
B.1.5. Definition of the methods for extracting data from studies
included from the systematic literature search
Data will be extracted from case reports and clinical trials. Extraction will be done in Microsoft
Excel®, where one reviewer will do the extraction, and another will validate it.
The items extracted will cover, e.g. RefID from DistillerSR® (Evidence Partners, Ottawa, Canada),
extraction date, author name, year, location, ALA dose, ALA as medicinal product or food supplement,
subject characteristics, duration of ALA consumption.
B.1.6. Definition of the methods for appraising evidence
No appraisal is foreseen.
B.1.7. Preliminary identification of the sources of uncertainty and
definition of the methods for prioritising them
For all questions identified in Section B.1.1, limited answers may be the consequence of lack of
data. Uncertainty analysis of the scientific assessment, i.e. identifying possible limitations in scientific
knowledge and assessing their implications for scientific conclusions, will be discussed briefly, based on
the EFSA guidance document on uncertainty (EFSA Scientific Committee, 2018). This implies in
particular identifying the sources of uncertainty affecting the assessment, prioritising these sources
based on their expected influence on the outcome/results and final overall discussions and planning
how the uncertainty analysis will be handled. It is expected that the following identified sources of
uncertainties will be discussed qualitatively (descriptive method) and no quantitative analysis will be
undertaken.
Uncertainties that might be encountered for question 1: Identity of ALA?, question 2: How is ALA
absorbed, distributed, metabolised and excreted? and question 3: what is IAS? (identified in
Section B.1.1):
• Lack of published data
Uncertainties that might be encountered for question 4: What is the association between ALA and
IAS in humans? and question 5: What is the minimum eliciting dose? (identified in Section B.1.1):
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o Exposure/compliance of subjects (in case of trials), i.e.
uncertainty of dose inducing IAS leading to possible over/underestimation.
o Insufficient reporting on the assessment/diagnosis of the adverse effects by investigators
▪ Potential misclassification of adverse effects
o Limited information on genetical susceptibility and impossibility to identify populations at risk.
o Publication bias
▪ Case reports may not all be published
▪ Adverse effects not adequately/extensively reported in trials
o Precision of the measurements made (if any)
o Power (for trials)
o Heterogeneity of the dataset
o Language of the SR
▪ Case reports published in non-EU languages will not be considered.
o Appraisal
▪ Due to time constrains it might not be feasible to conduct one.
o Representativity
▪ Relevance for the EU population will be assessed by expert judgement, as the case
reports are expected to be from a limited number of countries.
B.1.8. Definition of the methods for synthesising evidence within the
sub-question
Question 4 (section B.1.1). What is the association between ALA and IAS in humans?
It will depend on the evidence that will be obtained. Possibly qualitative.
Question 5 (section B.1.1). What is the minimum eliciting dose?
It will depend on the evidence that will be obtained. Possibly semi-quantitative. Expert knowledge
elicitation (EKE) might be needed, taking into account the relevant EFSA guidance (EFSA, 2014).
B.1.9. Definition of the methods for analysing uncertainties individually
and combined
Uncertainties will be identified at each step of the assessment, but no formal uncertainty
assessment is foreseen.
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Date of the search 4-9-2020
Set Query Results
#8 #5 AND #6 AND ([basque]/lim OR [bulgarian]/lim OR [catalan]/lim OR [croatian]/lim OR
[czech]/lim OR [danish]/lim OR [dutch]/lim OR [english]/lim OR [estonian]/lim OR [finnish]/
lim OR [french]/lim OR [german]/lim OR [greek]/lim OR [hungarian]/lim OR [irish gaelic]/lim
OR [italian]/lim OR [latvian]/lim OR [lithuanian]/lim OR [macedonian]/lim OR [norwegian]/
lim OR [polish]/lim OR [polyglot]/lim OR [portuguese]/lim OR [romanian]/lim OR [scottish
gaelic]/lim OR [serbian]/lim OR [slovak]/lim OR [slovenian]/lim OR [spanish]/lim OR
[swedish]/lim)
154
#7 #5 AND #6 160
#6 ‘hirata disease’/exp OR ‘hypoglycemia’/exp OR ‘insulin autoimmune syndrome’/exp OR aih:ti,
ab,kw OR (‘insulin’/exp AND (‘immunopathology’/de OR ‘immune system’/de OR
‘autoimmune disease’/de)) OR ((hirata* NEAR/3 disease*):ti,ab,kw) OR hypoglycaemia:ti,ab,
kw OR hypoglycaemic:ti,ab,kw OR hypoglycemia:ti,ab,kw OR hypoglycemic:ti,ab,kw OR ias:
ti,ab,kw OR ((insulin NEAR/5 autoimmune):ti,ab,kw)
134,940
#5 #3 OR #4 10,181
#4 alipure:ti,ab,kw OR ‘alpha-lipogamma’:ti,ab,kw OR ‘alphalipogamma’:ti,ab,kw OR ‘alpha-
lipon’:ti,ab,kw OR alphalipon:ti,ab,kw OR ‘alpha liponaure’:ti,ab,kw OR alphaliponaure:ti,ab,
kw OR alphaliponsaure:ti,ab,kw OR ‘alpha liponsaure’:ti,ab,kw OR ‘alpha lippon’:ti,ab,kw OR
alphalippon:ti,ab,kw OR ‘alpha vibolex’:ti,ab,kw OR alphavibolex:ti,ab,kw OR azulipont:ti,ab,
kw OR berlition:ti,ab,kw OR berlithione:ti,ab,kw OR biletan:ti,ab,kw OR ‘biomo lipon’:ti,ab,
kw OR biomolipon:ti,ab,kw OR ‘byodinoral r’:ti,ab,kw OR ‘coenzyme compositum’:ti,ab,kw
OR ‘discus compositum’:ti,ab,kw OR duralipon:ti,ab,kw OR ‘espa lipon’:ti,ab,kw OR
espalipon:ti,ab,kw OR fenint:ti,ab,kw OR ‘hepar compositium’:ti,ab,kw OR heparlipon:ti,ab,
kw OR juthiac:ti,ab,kw OR ‘ledum compositum’:ti,ab,kw OR ‘lycopodium compositum’:ti,ab,
kw OR liposan:ti,ab,kw OR ‘liponsaure-ratiopharm’:ti,ab,kw OR liponsaureratiopharm:ti,ab,
kw OR lipothion:ti,ab,kw OR mtwalphaliponsaure:ti,ab,kw OR neurium:ti,ab,kw OR
octolipen:ti,ab,kw OR oktolipen:ti,ab,kw OR ‘pleomix alpha’:ti,ab,kw OR ‘quamtrax ala’:ti,ab,
kw OR thioctacid:ti,ab,kw OR thioctacide:ti,ab,kw OR thioctan:ti,ab,kw OR thioctsan:ti,ab,kw
OR thiogamma:ti,ab,kw OR thiotacid:ti,ab,kw OR tromlipon:ti,ab,kw OR tioctacid:ti,ab,kw
OR tioctan:ti,ab,kw OR tioctidasi:ti,ab,kw OR ‘ubichinon compositum’:ti,ab,kw OR ‘verla
lipon’:ti,ab,kw OR verlalipon:ti,ab,kw OR zeel:ti,ab
141
#3 #1 OR #2 10,122
#2 ((‘1 2 dithiolan 3 pentanic’ OR 12dithiolan3pentanic OR ‘1 2 dithiolane 3 pentanoic’ OR
‘12dithiolane3pentanoic’ OR ‘1 2 dithiolane 3 valeric’ OR ‘12dithiolane3valeric’ OR ‘5 dithiolan
3 yl valeric’ OR ‘5dithiolan3ylvaleric’ OR ‘5 1 2 dithiolan 3 yl valeric’ OR 512ditiolan3ylvaleric
OR 68thioctic OR ‘6 8thioctic acid’ OR alipoic OR alipoic OR lipoic OR liponic OR thioctic OR
tioctic) NEAR/3 (acid OR acids)):ti,ab,kw
6,833
#1 ‘thioctic acid’/exp OR ‘1077 28 7’:ti,ab,kw OR 1077287:ti,ab,kw 9,259
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PubMed
Date of the search: 04-09-2020
Search Query Results
#6 Search: #5 AND (“bulgarian”[Language] OR “catalan”[Language] OR
“croatian”[Language] OR “czech”[Language] OR “danish”[Language] OR
“dutch”[Language] OR “english”[Language] OR “estonian”[Language] OR
“finnish”[Language] OR “french”[Language] OR “german”[Language] OR “greek
modern”[Language] OR “hungarian”[Language] OR “italian”[Language] OR
“latvian”[Language] OR “lithuanian”[Language] OR “multiple languages”[Language] OR
“norwegian”[Language] OR “polish”[Language] OR “portuguese”[Language] OR
“romanian”[Language] OR “scottish gaelic”[Language] OR “serbian”[Language] OR
“slovak”[Language] OR “slovenian”[Language] OR “spanish”[Language] OR
“swedish”[Language] OR “undetermined”[Language] OR “welsh”[Language]) Sort by:
Most Recent
54
#5 Search: #3 AND #4 59
#4 Search: (“Insulin”[Mesh] AND (“Immune System Diseases”[Mesh:noexp] OR “Immune
System”[Mesh:noexp] OR “Autoimmune Diseases”[Mesh:noexp])) OR
“Hypoglycemia”[Mesh] OR aih[tiab] OR (hirata*[tiab] AND disease*[tiab]) OR
Hypoglycaemia[tiab] OR Hypoglycaemic[tiab] OR Hypoglycemia[tiab] OR Hypoglycemic
[tiab] OR ias[tiab] OR (Insulin[tiab] AND autoimmune[tiab])
76,375
#3 Search: #1 OR #2 Sort by: Most Recent 6,051
#2 Search: “Thioctic Acid”[Mesh] OR “1077-28-7”[tiab] OR 1077287[tiab] OR “1,2-
Dithiolan-3-pentanic acid”[tiab] OR “1,2-Dithiolan-3-pentanic acids”[tiab] OR “1 2
dithiolane 3 pentanoic acid”[tiab] OR “12dithiolane3pentanoic acid”[tiab] OR “1 2
dithiolane 3 valeric acid”[tiab] OR ‘“2dithiolane3valeric acid”[tiab] OR “5 dithiolan 3 yl
valeric acid”[tiab] OR “5dithiolan3ylvaleric acid”[tiab] OR “5 1 2 dithiolan 3 yl valeric
acid”[tiab] OR “512ditiolan3ylvaleric acid”[tiab] OR “1 2 dithiolane 3 pentanoic
acids”[tiab] OR “12dithiolane3pentanoic acids”[tiab] OR “1 2 dithiolane 3 valeric
acids”[tiab] OR ‘“2dithiolane3valeric acids”[tiab] OR “5 dithiolan 3 yl valeric acids”[tiab]
OR “5dithiolan3ylvaleric acids”[tiab] OR “5 1 2 dithiolan 3 yl valeric acids”[tiab] OR
“512ditiolan3ylvaleric acids”[tiab] OR “68thioctic acid”[tiab] OR “68thioctic acids”[tiab]
OR “6 8thioctic acid”[tiab] OR “6 8thioctic acids”[tiab] OR “alipoic acid”[tiab] OR “alipoic
acids”[tiab] OR “lipoic acid”[tiab] OR “lipoic acids”[tiab] OR “liponic acid”[tiab] OR
“liponic acids”[tiab] OR “thioctic acid”[tiab] OR “thioctic acids”[tiab] OR “tioctic
acid”[tiab] OR “tioctic acids”[tiab]
6.014
#1 Search: Alipure[tiab] OR “Alpha-Lipogamma”[tiab] OR “AlphaLipogamma”[tiab] OR
“Alpha-Lipon”[tiab] OR AlphaLipon[tiab] OR “alpha Liponaure”[tiab] OR alphaLiponaure
[tiab] OR AlphaLiponsaure[tiab] OR “Alpha-Liponsaure”[tiab] OR “Alpha Lippon”[tiab] OR
AlphaLippon[tiab] OR “Alpha Vibolex”[tiab] OR alphaVibolex[tiab] OR Azulipont[tiab] OR
Berlithion[tiab] OR Berlithione[tiab] OR Biletan[tiab] OR “Biomo lipon”[tiab] OR
Biomolipon[tiab] OR “Byodinoral R”[tiab] OR “coenzyme compositum”[tiab] OR “discus
compositum”[tiab] OR Duralipon[tiab] OR “Espa-lipon”[tiab] OR Espalipon[tiab] OR
Fenint[tiab] OR “Hepar compositum”[tiab] OR Heparlipon[tiab] OR Juthiac[tiab] OR
“Lycopodium compositum”[tiab] OR “Ledum compositum”[tiab] OR Liposan[tiab] OR
“Liponsaure-ratiopharm”[tiab] OR Liponsaureratiopharm[tiab] OR Lipothion [tiab] OR
MTWAlphaliponsaure[tiab] OR Neurium[tiab] OR Octolipen[tiab] OR Oktolipen[tiab] OR
“Pleomix Alpha”[tiab] OR “Quamtrax ALA”[tiab] OR Thioctacid[tiab] OR Thioctacide[tiab]
OR Thioctan[tiab] OR Thioctsan[tiab] OR Thiogamma[tiab] OR Thiotacid[tiab] OR
Tromlipon[tiab] OR Tioctacid[tiab] OR Tioctidasi[tiab] OR Tioctan[tiab] OR Tioctidasi
[tiab] OR “Ubichinon compositum”[tiab] OR “Verla Lipon”[tiab] OR VerlaLipon[tiab] OR
Zeel[tiab]
78
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Search 2
Embase
Date of the search: 4-9-2020
Set Query Results
#6 #5 AND #4 123
#5 ‘meta analysis’/exp OR ’meta analysis (topic)’/exp OR ’review’/exp OR ’systematic review
(topic)’/exp OR ’biomedical technology assessment’/exp OR (((systematic* OR
methodologic* OR quantitative OR research OR integrative OR collaborative) NEAR/
3 overview*):ti,ab) OR review*:ti,ab,kw OR ((pool* NEAR/3 analy*):ti,ab)
36,427,795
#4 #3 AND ([basque]/lim OR [bulgarian]/lim OR [catalan]/lim OR [croatian]/lim OR [czech]/lim
OR [danish]/lim OR [dutch]/lim OR [english]/lim OR [estonian]/lim OR [finnish]/lim OR
[french]/lim OR [german]/lim OR [hungarian]/lim OR [norwegian]/lim OR [polish]/lim OR
[polyglot]/lim OR [portuguese]/lim OR [romanian]/lim OR [scottish gaelic]/lim OR [serbian]/
lim OR [slovak]/lim OR [slovenian]/lim OR [spanish]/lim OR [swedish]/lim)
699
#3 #1 OR #2 775
#2 ((autoimmune NEAR/3 (hypoglycaemia OR hypoglycemia)):ti,ab,kw) OR (((‘insulin
autoimmune’ OR ‘autoimmune insulin’) NEAR/3 (syndrom* OR disease*)):ti,ab,kw) OR
((endogenous NEAR/3 hyperinsulinemic NEAR/3 (hypoglycaemia OR hypoglycemia)):ti,ab,
kw) OR ((hirata* NEAR/3 disease*):ti,ab,kw) OR ((insulin NEAR/3 autoimmune NEAR/3
(hypoglycaemia OR hypoglycemia)):ti,ab,kw) OR ‘insulin autoimmunity’:ti,ab,kw OR
((spontaneous NEAR/3 (hypoglycaemia OR hypoglycemia) NEAR/3 (attack* OR insulin)):ti,
ab,kw) OR ((insulinNEAR/3 (‘autoimmune disease’ OR ’autoimmune
diseases’ OR ’autoimmune syndrome’ OR ’autoimmune syndromes’)):ti,ab,kw)
761
#1 ‘hirata disease’/exp OR ‘insulin autoimmune syndrome’/exp 107
PubMed
Date of the search: 4-9-2020
Search Query Results
#5 Search: #4 AND #3 187
#4 Search: “review”[sb] OR “systematic”[sb] OR “meta-analysis”[pt] OR “meta-analysis
as topic”[Mesh] OR “meta-analysis”[Mesh] OR meta analy*[tw] OR metanaly*[tw] OR
metaanaly*[tw] OR met analy*[tw] OR integrative research[tiab] OR review*[tiab]
OR integrative overview*[tiab] OR research integration*[tiab] OR research overview*
[tiab] OR comparative efficacy[tiab] OR comparative effectiveness[tiab] OR outcomes
research[tiab] OR indirect comparison*[tiab] OR Embase*[tiab] OR Cinahl*[tiab] OR
systematic overview*[tiab] OR methodological overview*[tiab] OR methodologic
overview*[tiab] OR methodological review*[tiab] OR methodologic review*[tiab] OR
quantitative review*[tiab] OR quantitative overview*[tiab] OR quantitative synthes*
[tiab] OR pooled analy*[tiab] OR Cochrane[tiab] OR Medline[tiab] OR Pubmed[tiab]
OR Medlars[tiab] OR handsearch*[tiab] OR hand search*[tiab] OR meta-regression*
[tiab] OR metaregression*[tiab] OR data synthes*[tiab] OR data extraction[tiab] OR
data abstraction*[tiab] OR mantel haenszel[tiab] OR peto[tiab] OR der-simonian[tiab]
OR dersimonian[tiab] OR fixed effect*[tiab] OR “Cochrane Database Syst
Rev”[Journal:__jrid21711]
3,795,869
#3 Search: #1 AND #2 Sort by: Most Recent 936
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Search Query Results
#2 Search: (“bulgarian”[Language] OR “catalan”[Language] OR “croatian”[Language] OR
“czech”[Language] OR “danish”[Language] OR “dutch”[Language] OR
“english”[Language] OR “estonian”[Language] OR “finnish”[Language] OR
“french”[Language] OR “german”[Language] OR “greek modern”[Language] OR
“hungarian”[Language] OR “italian”[Language] OR “latvian”[Language] OR
“lithuanian”[Language] OR “multiple languages”[Language] OR
“norwegian”[Language] OR “polish”[Language] OR “portuguese”[Language] OR
“romanian”[Language] OR “scottish gaelic”[Language] OR “serbian”[Language] OR
“slovak”[Language] OR “slovenian”[Language] OR “spanish”[Language] OR
“swedish”[Language] OR “undetermined”[Language] OR “welsh”[Language]) Sort
by: Most Recent
29,780,296
#1 Search: (autoimmune hypoglycaemia[tiab] OR autoimmune hypoglycaemia[tiab] OR
((“insulin autoimmune”[tiab] OR “autoimmune insulin”[tiab]) AND syndrom*[tiab])OR
“insulin autoimmune disease”[tiab] OR “insulin autoimmune diseases”[tiab] OR
(endogenous[tiab] AND hyperinsulinemic[tiab] AND (hypoglycaemia[tiab] OR
hypoglycemia[tiab])) OR (hirata*[tiab] AND disease*[tiab]) OR (insulin[tiab] AND
autoimmune[tiab] AND (hypoglycaemia[tiab] OR hypoglycemia[tiab])) OR “insulin
autoimmunity”[tiab] OR (spontaneous[tiab] AND (hypoglycaemia[tiab] OR
hypoglycemia[tiab]) AND (attack*[tiab] OR insulin[tiab])) OR (insulin[tiab] AND
(“autoimmune syndrome”[tiab] OR “autoimmune syndromes”[tiab])) OR (“insulin




Date of the search: 4-9-2020
Set Query Results
#17 #16 NOT #17 AND [english]/lim 2,203
#18 #16 NOT #17 2,400
#17 (rat:ti OR rats:ti OR mouse:ti OR mice:ti OR swine:ti OR porcine:ti OR murine:ti
OR sheep:ti OR lambs:ti OR pigs:ti OR piglets:ti OR rabbit:ti OR rabbits:ti OR cat:ti
OR cats:ti OR dog:ti OR dogs:ti OR cattle:ti OR bovine:ti OR monkey:ti OR monkeys:ti
OR trout:ti OR marmoset*:ti) AND ’animal experiment’/de
1,077,288
#16 #14 NOT #15 2,405
#15 ‘animal experiment’/de NOT (‘human experiment’/de OR ‘human’/de) 2,272,297
#14 #5 AND #13 3,014
#13 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 5,520,026
#12 ((data NEAR/1 (synthes* OR extraction* OR abstraction*)):ti,ab) OR handsearch*:ti,ab
OR ‘hand search’:ti,ab OR ’hand searches’:ti,ab OR ’hand searching’:ti,ab OR ‘mantel
haenszel’:ti,ab OR peto:ti,ab OR ‘der simonian’:ti,ab OR dersimonian:ti,ab OR ‘fixed
effect’:ti,ab OR ‘fixed effects’:ti,ab OR ‘latin square’:ti,ab OR ‘latin squares’:ti,ab OR ‘meta
analysis’:ti,ab OR ‘meta analyses’:ti,ab OR ‘met analysis’:ti,ab OR ‘met analyses’:ti,ab
OR metaanaly*:ti,ab OR metanaly*:ti,ab OR ‘meta regression’:ti,ab OR ‘meta
regressions’:ti,ab OR metaregression*:ti,ab OR medline:ti,ab OR cochrane:ti,ab
OR pubmed:ti,ab OR medlars:ti,ab OR embase:ti,ab OR cinahl:ti,ab OR cochrane:jt
OR ‘evidence report’:jt OR ((comparative NEAR/3 (efficacy OR effectiveness)):ti,ab)
OR ‘outcomes research’:ti,ab OR ‘relative effectiveness’:ti,ab OR (((indirect OR ‘indirect
treatment’ OR ‘mixed treatment’) NEAR/3 comparison):ti,ab)
475,049
#11 ((systematic* NEAR/3 (review* OR overview*)):ti,ab) OR ((methodologic* NEAR/3
(review* OR overview*)):ti,ab) OR ((quantitative NEAR/3
(review* OR overview* OR synthes*)):ti,ab) OR ((research NEAR/3
(integrati* OR overview*)):ti,ab) OR ((integrative NEAR/3 (review* OR overview*)):ti,ab)
OR ((collaborative NEAR/3 (review* OR overview*)):ti,ab) OR ((pool* NEAR/3 analy*):ti,
ab)
283,769
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Set Query Results
#10 ‘meta analysis’/exp OR ’meta analysis (topic)’/exp OR ’systematic review’/exp
OR ’systematic review (topic)’/exp OR ’biomedical technology assessment’/exp
415,886
#9 ‘crossover procedure’/exp OR (((crossover OR ’cross over’) NEAR/10
(study OR studies OR design* OR method* OR procedure OR comparison)):ti,ab)
94,585
#8 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/10 (mask* OR blind* OR dumm*)):ti,ab 252,294
#7 ‘clinical trial (topic)’/exp OR ’double blind procedure’/exp OR ’single blind procedure’/exp
OR ’triple blind procedure’/exp
542,371
#6 ‘clinical trial’/exp OR ’randomization’/exp OR randomized:ti,ab OR randomised:ti,ab
OR placebo:ti,ab OR randomly:ti,ab OR trial:ti,ab OR groups:ti,ab
4,935,446
#5 #3 OR #4 10,181
#4 alipure:ti,ab,kw OR ‘alpha-lipogamma’:ti,ab,kw OR ‘alphalipogamma’:ti,ab,kw OR ‘alpha-
lipon’:ti,ab,kw OR alphalipon:ti,ab,kw OR ‘alpha liponaure’:ti,ab,kw OR alphaliponaure:ti,
ab,kw OR alphaliponsaure:ti,ab,kw OR ‘alpha liponsaure’:ti,ab,kw OR ‘alpha lippon’:ti,ab,kw
OR alphalippon:ti,ab,kw OR ‘alpha vibolex’:ti,ab,kw OR alphavibolex:ti,ab,kw OR azulipont:
ti,ab,kw OR berlition:ti,ab,kw OR berlithione:ti,ab,kw OR biletan:ti,ab,kw OR ‘biomo lipon’:
ti,ab,kw OR biomolipon:ti,ab,kw OR ‘byodinoral r’:ti,ab,kw OR ‘coenzyme compositum’:ti,
ab,kw OR ‘discus compositum’:ti,ab,kw OR duralipon:ti,ab,kw OR ‘espa lipon’:ti,ab,kw OR
espalipon:ti,ab,kw OR fenint:ti,ab,kw OR ‘hepar compositium’:ti,ab,kw OR heparlipon:ti,ab,
kw OR juthiac:ti,ab,kw OR ‘ledum compositum’:ti,ab,kw OR ‘lycopodium compositum’:ti,ab,
kw OR liposan:ti,ab,kw OR ‘liponsaure-ratiopharm’:ti,ab,kw OR liponsaureratiopharm:ti,ab,
kw OR lipothion:ti,ab,kw OR mtwalphaliponsaure:ti,ab,kw OR neurium:ti,ab,kw OR
octolipen:ti,ab,kw OR oktolipen:ti,ab,kw OR ‘pleomix alpha’:ti,ab,kw OR ‘quamtrax ala’:ti,
ab,kw OR thioctacid:ti,ab,kw OR thioctacide:ti,ab,kw OR thioctan:ti,ab,kw OR thioctsan:ti,
ab,kw OR thiogamma:ti,ab,kw OR thiotacid:ti,ab,kw OR tromlipon:ti,ab,kw OR tioctacid:ti,
ab,kw OR tioctan:ti,ab,kw OR tioctidasi:ti,ab,kw OR ‘ubichinon compositum’:ti,ab,kw OR
‘verla lipon’:ti,ab,kw OR verlalipon:ti,ab,kw OR zeel:ti,ab
141
#3 #1 OR #2 10,112
#2 ((‘1 2 dithiolan 3 pentanic’ OR 12dithiolan3pentanic OR ’1 2 dithiolane 3
pentanoic’ OR ’12dithiolane3pentanoic’ OR ’1 2 dithiolane 3
valeric’ OR ’12dithiolane3valeric’ OR ’5 dithiolan 3 yl valeric’ OR ’5dithiolan3ylvaleric’ OR ’5
1 2 dithiolan 3 yl valeric’ OR 512ditiolan3ylvaleric OR 68thioctic OR ’6 8thioctic
acid’ OR alipoic OR alipoic OR lipoic OR liponic OR thioctic OR tioctic) NEAR/3
(acidOR acids)):ti,ab,kw
6,833
#1 ‘thioctic acid’/exp OR ’1077 28 7’:ti,ab,kw OR 1077287:ti,ab,kw 9,259
PubMed
Date of the search: 4-9-2020
Search Query Results
#12 Search: “english”[Language] AND #11 772
#11 Search: #9 NOT #10 843
#10 Search: (rat[ti] OR rats[ti] OR mouse[ti] OR mice[ti] OR swine[ti] OR porcine[ti] OR
murine[ti] OR sheep[ti] OR lambs[ti] OR pigs[ti] OR piglets[ti] OR rabbit[ti] OR rabbits
[ti] OR cat[ti] OR cats[ti] OR dog[ti] OR dogs[ti] OR cattle[ti] OR bovine[ti] OR
monkey[ti] OR monkeys[ti] OR trout[ti] OR marmoset*[ti])
2,021,263
#9 Search: #7 NOT #8 934
#8 Search: (“Animals”[Mesh] NOT (“Animals”[Mesh] AND “Humans”[Mesh])) 4,731,720
#7 Search: #6 AND #3 1,511
#6 Search: #4 OR #5 3,788,408
alpha-Lipoic acid and risk of insulin autoimmune syndrome
www.efsa.europa.eu/efsajournal 41 EFSA Journal 2021;19(6):6577
Search Query Results
#5 Search: “clinical trial”[pt] OR “Random Allocation”[Mesh] OR randomized[tiab] OR
randomised[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]
OR “Clinical Trials as Topic”[Mesh] OR “Double-Blind Method”[Mesh] OR “Single-Blind
Method”[Mesh] OR ((singl*[tiab] OR doubl*[tiab] OR trebl*[tiab] OR tripl*[tiab]) AND
(mask*[tiab] OR blind*[tiab] OR dumm*[tiab])) OR “Cross-Over Studies”[Mesh] OR
((crossover[tiab] OR “cross over”[tiab]) AND (study[tiab] OR studies[tiab] OR design*
[tiab] OR method*[tiab] OR procedure[tiab] OR comparison[tiab]))
3,516,499
#4 Search: systematic[sb] OR meta-analysis[pt] OR meta-analysis as topic[Mesh] OR
meta-analysis[Mesh] OR meta analy*[tw] OR metanaly*[tw] OR metaanaly*[tw] OR
met analy*[tw] OR integrative research[tiab] OR integrative review*[tiab] OR
integrative overview*[tiab] OR research integration*[tiab] OR research overview*[tiab]
OR collaborative review*[tiab] OR collaborative overview*[tiab] OR systematic review*
[tiab] OR comparative efficacy[tiab] OR comparative effectiveness[tiab] OR outcomes
research[tiab] OR indirect comparison*[tiab] OR Embase*[tiab] OR Cinahl*[tiab] OR
systematic overview*[tiab] OR methodological overview*[tiab] OR methodologic
overview*[tiab] OR methodological review*[tiab] OR methodologic review*[tiab] OR
quantitative review*[tiab] OR quantitative overview*[tiab] OR quantitative synthes*
[tiab] OR pooled analy*[tiab] OR Cochrane[tiab] OR Medline[tiab] OR Pubmed[tiab]
OR Medlars[tiab] OR handsearch*[tiab] OR hand search*[tiab] OR meta-regression*
[tiab] OR metaregression*[tiab] OR data synthes*[tiab] OR data extraction[tiab] OR
data abstraction*[tiab] OR mantel haenszel[tiab] OR peto[tiab] OR der-simonian[tiab]
OR dersimonian[tiab] OR fixed effect*[tiab] OR “Cochrane Database Syst
Rev”[Journal:__jrid21711]
433,871
#3 Search: #1 OR #2 Sort by: Most Recent 6,014
#2 Search: “Thioctic Acid”[Mesh] OR “1077-28-7”[tiab] OR 1077287[tiab] OR “1,2-
Dithiolan-3-pentanic acid”[tiab] OR “1,2-Dithiolan-3-pentanic acids”[tiab] OR “1 2
dithiolane 3 pentanoic acid”[tiab] OR “12dithiolane3pentanoic acid”[tiab] OR “1 2
dithiolane 3 valeric acid”[tiab] OR ‘“2dithiolane3valeric acid”[tiab] OR “5 dithiolan 3 yl
valeric acid”[tiab] OR “5dithiolan3ylvaleric acid”[tiab] OR “5 1 2 dithiolan 3 yl valeric
acid”[tiab] OR “512ditiolan3ylvaleric acid”[tiab] OR “1 2 dithiolane 3 pentanoic
acids”[tiab] OR “12dithiolane3pentanoic acids”[tiab] OR “1 2 dithiolane 3 valeric
acids”[tiab] OR ‘“2dithiolane3valeric acids”[tiab] OR “5 dithiolan 3 yl valeric acids”[tiab]
OR “5dithiolan3ylvaleric acids”[tiab] OR “5 1 2 dithiolan 3 yl valeric acids”[tiab] OR
“512ditiolan3ylvaleric acids”[tiab] OR “68thioctic acid”[tiab] OR “68thioctic acids”[tiab]
OR “6 8thioctic acid”[tiab] OR “6 8thioctic acids”[tiab] OR “alipoic acid”[tiab] OR
“alipoic acids”[tiab] OR “lipoic acid”[tiab] OR “lipoic acids”[tiab] OR “liponic acid”[tiab]
OR “liponic acids”[tiab] OR “thioctic acid”[tiab] OR “thioctic acids”[tiab] OR “tioctic
acid”[tiab] OR “tioctic acids”[tiab]
5,970
#1 Search: Alipure[tiab] OR “Alpha-Lipogamma”[tiab] OR “AlphaLipogamma”[tiab] OR
“Alpha-Lipon”[tiab] OR AlphaLipon[tiab] OR “alpha Liponaure”[tiab] OR alphaLiponaure
[tiab] OR AlphaLiponsaure[tiab] OR “Alpha-Liponsaure”[tiab] OR “Alpha Lippon”[tiab]
OR AlphaLippon[tiab] OR “Alpha Vibolex”[tiab] OR alphaVibolex[tiab] OR Azulipont
[tiab] OR Berlithion[tiab] OR Berlithione[tiab] OR Biletan[tiab] OR “Biomo lipon”[tiab]
OR Biomolipon[tiab] OR “Byodinoral R”[tiab] OR “coenzyme compositum”[tiab] OR
“discus compositum”[tiab] OR Duralipon[tiab] OR “Espa-lipon”[tiab] OR Espalipon[tiab]
OR Fenint[tiab] OR “Hepar compositum”[tiab] OR Heparlipon[tiab] OR Juthiac[tiab] OR
“Lycopodium compositum”[tiab] OR “Ledum compositum”[tiab] OR Liposan[tiab] OR
“Liponsaure-ratiopharm”[tiab] OR Liponsaureratiopharm[tiab] OR Lipothion [tiab] OR
MTWAlphaliponsaure[tiab] OR Neurium[tiab] OR Octolipen[tiab] OR Oktolipen[tiab] OR
“Pleomix Alpha”[tiab] OR “Quamtrax ALA”[tiab] OR Thioctacid[tiab] OR Thioctacide
[tiab] OR Thioctan[tiab] OR Thioctsan[tiab] OR Thiogamma[tiab] OR Thiotacid[tiab]
OR Tromlipon[tiab] OR Tioctacid[tiab] OR Tioctidasi[tiab] OR Tioctan[tiab] OR
Tioctidasi[tiab] OR “Ubichinon compositum”[tiab] OR “Verla Lipon”[tiab] OR VerlaLipon
[tiab] OR Zeel[tiab]
78
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Appendix D – Search strings for the fourth literature search performed
after public consultation
Embase
Date of the search 1/3/1021
Set Query Results Comments
#6 #1 AND #4 AND [humans]/lim 271 Dihydrolipoic acid AND
ADME AND Humans
#5 #1 AND #4 674 Dihydrolipoic acid AND
ADME
#4 #2 OR #3 15,430,136 ADME
#3 adme:ti,ab,kw OR admet:ti,ab,kw OR activat*:ti,ab,
kw OR administ*:ti,ab,kw OR absorpt*:ti,ab,kw
OR bioavailab*:ti,ab,kw OR bioconcentrat*:ti,ab,kw
OR biotransform*:ti,ab,kw OR clear*:ti,ab,kw
OR concentrat*:ti,ab,kw OR diffus*:ti,ab,kw
OR distribut*:ti,ab,kw OR eliminat*:ti,ab,kw
OR excret*:ti,ab,kw OR ’half life’:ti,ab,kw
OR metaboli*:ti,ab,kw OR pbk:ti,ab,kw OR pbpk:ti,
ab,kw OR pharmacokinetic*:ti,ab,kw
OR pharmacodynamic*:ti,ab,kw OR resorpt*:ti,ab,
kw OR ’systemic circulation’:ti,ab,kw
OR toxicokinetic*:ti,ab,kw OR transfer*:ti,ab,kw
OR transport*:ti,ab,kw
10,873,475 ADME 2
#2 ‘pharmacokinetics’/exp OR ’absorption’/de
OR ’distribution’/exp OR ’metabolism’/exp
OR ’excretion’/exp OR ’pharmacodynamics’/exp
9,045,217 ADME 1
#1 ‘dihydrolipoate’/exp OR ‘462 20 4’:ti,ab,kw
OR dihydrolipoate:ti,ab,kw OR
(((dihydrolipoic OR dihydrothioctic OR ‘dihydro
thioctic’ OR ‘6 8 dimercaptooctanoic’ OR ‘6 8
dimercapto octane’ OR ‘6 8
dimercaptooctane’ OR ‘6 8
dimercaptocaprylic’ OR ‘6 8
dithiooctanoic’ OR ‘dihydro a lipoic’ OR ‘dihydro
alpha lipoic’ OR dihydroalphalipoic OR ‘reduced
lipoic’ OR ‘reduced thioctic’ OR ‘c
lipoic’ OR clipoic OR ‘gamma
lipoic’ OR gammalipoic OR thioctanic) NEAR/
3 acid*):ti,ab,kw)
805 Dihydrolipoic acid
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Scopus
Date of the search 1/3/1021
Set Search Results Comments
#8 ((((CASREGNUMBER (462-20-4)) OR (TITLE-ABS-
KEY (dihydrolipoate OR ((dihydrolipoic OR dihydrothioctic OR
“dihydro Thioctic” OR “6 8 Dimercaptooctanoic” OR “6 8
dimercapto octane” OR “6 8 dimercaptooctane” OR “6 8
dimercaptocaprylic” OR “6 8 dithiooctanoic” OR “dihydro a lipoic”
OR “dihydro a lipoic” OR “dihydro alpha lipoic” OR
dihydroalphalipoic OR “reduced lipoic” OR “lipoic reduced” OR
“reduced thioctic” OR “thioctic reduced” OR “c lipoic” OR clipoic
OR “gamma lipoic” OR gammalipoic OR thioctanic) W/3 acid*))))
AND (TITLE-ABS-KEY (adme OR admet OR activat* OR administ*
OR absorpt* OR bioavailab* OR bioconcentrat* OR biotransform*
OR clear* OR concentrat* OR diffus* OR distribut* OR eliminat*
OR excret* OR “half life” OR metaboli* OR pbk OR pbpk OR
pharmacokinetic* OR pharmacodynamic* OR resorpt* OR
“systemic circulation” OR toxicokinetic* OR transfer* OR
transport*))) AND ((INDEXTERMS (humans OR human)))) OR
((((CASREGNUMBER (462-20-4)) OR (TITLE-ABS-
KEY (dihydrolipoate OR ((dihydrolipoic OR dihydrothioctic OR
“dihydro Thioctic” OR “6 8 Dimercaptooctanoic” OR “6 8
dimercapto octane” OR “6 8 dimercaptooctane” OR “6 8
dimercaptocaprylic” OR “6 8 dithiooctanoic” OR “dihydro a lipoic”
OR “dihydro a lipoic” OR “dihydro alpha lipoic” OR
dihydroalphalipoic OR “reduced lipoic” OR “lipoic reduced” OR
“reduced thioctic” OR “thioctic reduced” OR “c lipoic” OR clipoic
OR “gamma lipoic” OR gammalipoic OR thioctanic) W/3 acid*))))
AND (TITLE-ABS-KEY (adme OR admet OR activat* OR administ*
OR absorpt* OR bioavailab* OR bioconcentrat* OR biotransform*
OR clear* OR concentrat* OR diffus* OR distribut* OR eliminat*
OR excret* OR “half life” OR metaboli* OR pbk OR pbpk OR
pharmacokinetic* OR pharmacodynamic* OR resorpt* OR
“systemic circulation” OR toxicokinetic* OR transfer* OR
transport*))) AND (TITLE-ABS-KEY ((human* OR patient* OR
women OR woman OR men OR man OR child OR children OR










#7 (((CASREGNUMBER (462-20-4)) OR (TITLE-ABS-
KEY (dihydrolipoate OR ((dihydrolipoic OR dihydrothioctic OR
“dihydro Thioctic” OR “6 8 Dimercaptooctanoic” OR “6 8
dimercapto octane” OR “6 8 dimercaptooctane” OR “6 8
dimercaptocaprylic” OR “6 8 dithiooctanoic” OR “dihydro a lipoic”
OR “dihydro a lipoic” OR “dihydro alpha lipoic” OR
dihydroalphalipoic OR “reduced lipoic” OR “lipoic reduced” OR
“reduced thioctic” OR “thioctic reduced” OR “c lipoic” OR clipoic
OR “gamma lipoic” OR gammalipoic OR thioctanic) W/3 acid*))))
AND (TITLE-ABS-KEY (adme OR admet OR activat* OR administ*
OR absorpt* OR bioavailab* OR bioconcentrat* OR biotransform*
OR clear* OR concentrat* OR diffus* OR distribut* OR eliminat*
OR excret* OR “half life” OR metaboli* OR pbk OR pbpk OR
pharmacokinetic* OR pharmacodynamic* OR resorpt* OR
“systemic circulation” OR toxicokinetic* OR transfer* OR
transport*))) AND (TITLE-ABS-KEY ((human* OR patient* OR
women OR woman OR men OR man OR child OR children OR





ADME AND Humans 2
alpha-Lipoic acid and risk of insulin autoimmune syndrome
www.efsa.europa.eu/efsajournal 44 EFSA Journal 2021;19(6):6577
Set Search Results Comments
#6 (((CASREGNUMBER (462-20-4)) OR (TITLE-ABS-
KEY (dihydrolipoate OR ((dihydrolipoic OR dihydrothioctic OR
“dihydro Thioctic” OR “6 8 Dimercaptooctanoic” OR “6 8
dimercapto octane” OR “6 8 dimercaptooctane” OR “6 8
dimercaptocaprylic” OR “6 8 dithiooctanoic” OR “dihydro a lipoic”
OR “dihydro a lipoic” OR “dihydro alpha lipoic” OR
dihydroalphalipoic OR “reduced lipoic” OR “lipoic reduced” OR
“reduced thioctic” OR “thioctic reduced” OR “c lipoic” OR clipoic
OR “gamma lipoic” OR gammalipoic OR thioctanic) W/3 acid*))))
AND (TITLE-ABS-KEY (adme OR admet OR activat* OR administ*
OR absorpt* OR bioavailab* OR bioconcentrat* OR biotransform*
OR clear* OR concentrat* OR diffus* OR distribut* OR eliminat*
OR excret* OR “half life” OR metaboli* OR pbk OR pbpk OR
pharmacokinetic* OR pharmacodynamic* OR resorpt* OR
“systemic circulation” OR toxicokinetic* OR transfer* OR
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#5 TITLE-ABS-KEY ((human* OR patient* OR women OR woman OR










#3 ((CASREGNUMBER (462-20-4)) OR (TITLE-ABS-
KEY (dihydrolipoate OR ((dihydrolipoic OR dihydrothioctic OR
“dihydro Thioctic” OR “6 8 Dimercaptooctanoic” OR “6 8
dimercapto octane” OR “6 8 dimercaptooctane” OR “6 8
dimercaptocaprylic” OR “6 8 dithiooctanoic” OR “dihydro a lipoic”
OR “dihydro a lipoic” OR “dihydro alpha lipoic” OR
dihydroalphalipoic OR “reduced lipoic” OR “lipoic reduced” OR
“reduced thioctic” OR “thioctic reduced” OR “c lipoic” OR clipoic
OR “gamma lipoic” OR gammalipoic OR thioctanic) W/3 acid*))))
AND (TITLE-ABS-KEY (adme OR admet OR activat* OR administ*
OR absorpt* OR bioavailab* OR bioconcentrat* OR biotransform*
OR clear* OR concentrat* OR diffus* OR distribut* OR eliminat*
OR excret* OR “half life” OR metaboli* OR pbk OR pbpk OR
pharmacokinetic* OR pharmacodynamic* OR resorpt* OR







#2 TITLE-ABS-KEY (adme OR admet OR activat* OR administ* OR
absorpt* OR bioavailab* OR bioconcentrat* OR biotransform* OR
clear* OR concentrat* OR diffus* OR distribut* OR eliminat* OR
excret* OR “half life” OR metaboli* OR pbk OR pbpk OR
pharmacokinetic* OR pharmacodynamic* OR resorpt* OR






#1 (CASREGNUMBER (462-20-4)) OR (TITLE-ABS-KEY (dihydrolipoate
OR ((dihydrolipoic OR dihydrothioctic OR “dihydro Thioctic” OR “6
8 Dimercaptooctanoic” OR “6 8 dimercapto octane” OR “6 8
dimercaptooctane” OR “6 8 dimercaptocaprylic” OR “6 8
dithiooctanoic” OR “dihydro a lipoic” OR “dihydro a lipoic” OR
“dihydro alpha lipoic” OR dihydroalphalipoic OR “reduced lipoic”
OR “lipoic reduced” OR “reduced thioctic” OR “thioctic reduced”
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Annex A – Outcome of a public consultation on the Scientific Opinion of
the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on the
relationship between intake of alpha-lipoic acid (thioctic acid) and the risk
of insulin autoimmune syndrome
Annex A can be found in the online version of this output (in the ‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2021.6577
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